Company · founded 2004
Cumberland Pharmaceuticals (United States)
Nashville, United States · cumberlandpharma.com
- Citations, last 5 years
- 49
- Works, last 5 years
- 12
- h-index
- 24
- Scientists listed
- 4
- Grants since 2016
- 5
Grants received
2020–2022 · research · R01
A Ph2 Randomized, Placebo-controlled, Multiple Dose Study to Determine the Safety, Pharmacokinetics and Efficacy of Oral Ifetroban in Subjects with Duchenne Musculary Dystrophy IND136895 (10/10/2018)
Ines Macias-Perez · Cumberland Pharmaceuticals (United States) · funded by U.S. Food and Drug Administration
2019–2024 · research · R01
A Ph2 Randomized, Placebo-controlled, Multiple Dose Study to Determine the Safety, Pharmacokinetics and Efficacy of Oral Ifetroban in Subjects with Duchenne Musculary Dystrophy IND136895 (10/10/2018)
Ines Macias-Perez · Cumberland Pharmaceuticals (United States) · funded by U.S. Food and Drug Administration
2018–2020 · research · R44
Targeting DNA damage response pathways for the treatment of advanced lung cancer
Michael L. Freeman · Cumberland Pharmaceuticals (United States) · funded by National Institutes of Health
2018–2021 · research · R44
Targeting DNA damage response pathways for the treatment of advanced lung cancer
Michael L. Freeman · Cumberland Pharmaceuticals (United States) · funded by National Institutes of Health
2016–2018 · research · R41
A simple and effective diagnostic test for gastrointestinal bleeding to improve patient outcomes
Henry Charles Manning · Cumberland Pharmaceuticals (United States) · funded by National Institutes of Health